Unlike 18F-FDG, which relies on glucose metabolism and is often limited by a high physiological uptake in the brain and inflammatory tissues, FAPI PET specifically targets fibroblast activation protein (FAP), which is overexpressed in cancer-associated fibroblasts (CAFs) within the tumor microenvironment. Here, FAP is linked to neoplasm.